Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antibody Subclass and Glycosylation Shift Following Effective TB Treatment

Frontiers in Immunology(2021)10.3389/fimmu.2021.679973Source: DataRank Database

Antibody Subclass and Glycosylation Shift Following Effective TB Treatment is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 54 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access54 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.13)OA: goldTopics (76)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Sepideh Dolatshahi ORCID,Lenette L. Lu ORCID,Adam Cain,Fabrizio Palmieri ORCID,Linda Petrone ORCID

Live enrichment

PubMed:34290702 PMC:PMC8287567 OpenAlex:https://openalex.org/W3184731290

NIAID NIH HHS

Grant: K08 AI130357

NIAID NIH HHS

Grant: T32 AI007061

National Institutes of Health

Grant: 5T32AI007061-25

INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMS

Massachusetts General Hospital

National Institutes of Health

FWCI

2.13

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.679973/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.679973/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.679973/full

journalhttps://doi.org/10.3389/fimmu.2021.679973

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34290702

Fields of Study

Tuberculosis Research and EpidemiologyMonoclonal and Polyclonal Antibodies ResearchMycobacterium research and diagnosis0301 basic medicine03 medical and health sciences0303 health sciencesAntibodies, BacterialAntigens, BacterialAntitubercular AgentsFemaleGlycosylationHost-Pathogen InteractionsHumansImmunoglobulin Fc FragmentsImmunoglobulin GKiller Cells, NaturalLatent TuberculosisMaleMycobacterium tuberculosisNeutrophilsPhagocytosisPolysaccharidesTuberculosis

MeSH Terms

Antibodies, BacterialAntigens, BacterialAntitubercular AgentsFemaleGlycosylationHumansImmunoglobulin GImmunoglobulin Fc FragmentsKiller Cells, NaturalMaleMycobacterium tuberculosisNeutrophilsPhagocytosisPolysaccharidesTuberculosisHost-Pathogen InteractionsLatent Tuberculosis

Keywords

ImmunologyAntibodySubclassTuberculosisMedicineMycobacterium tuberculosisSialic acidDiseaseGlycanLatent tuberculosisHumoral immunityVirologyBiologyGlycoproteinInternal medicinePathologyAntibodiesIgg4Tb TherapyFc-glycosylationMaleGlycosylationNeutrophilsAntitubercular AgentsPhagocytosisPolysaccharidesHumansAntigens, BacterialRC581-607Antibodies, BacterialImmunoglobulin Fc FragmentsKiller Cells, NaturalImmunoglobulin GHost-Pathogen InteractionsFemaleImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Reduced inequalities

Antibody Subclass and Glycosylation Shift Following Effective TB Treatment

FAIR Checklist

Authors (12)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)